Molecular biomarkers commonly used to predict cancer responses to immunotherapy include Programmed Death-ligand 1 (PD-L1) expression (32), tumor-associated antigens (33), Human Leukocyte Antigen (HLA) expression (34), T Cell Receptor (TCR) repertoire assessment (35), tumor mutational burden and neoantigen identification (36), mismatch repair deficiencies, presence of tumor-infiltrating lymphocytes, and cells within the tumor microenvironment that may inhibit antitumor immune responses (37). Here, CD274 is linked to neoplasm.